Histone Deacetylase 10-inhibitor Co-Treatment in Cancer
Histone deacetylase inhibitors (HDACi) are promising anticancer agents and are currently being evaluated in clinical trials. However, due to their unselective action, pan-HDACi exhibit dose-limiting side-effects restricting their full potential in anti-cancer therapy. Therefore, characterization of the molecular function of single HDAC isozymes is of major importance for a targeted therapy with less side-effects. We show that HDAC10 overexpression mediated cell survival and targeting of HDAC10 sensitized tumor cells for cytotoxic drug treatment and it correlates with progression or recurrence of neuroblastoma in vivo. These results demonstrate for the first time that HDAC10 induces an alternative lysosomal-mediated tumor cell death pathway, re-sensitizes cells for cytotoxic drugs and may thus be a novel strategy for neuroblastoma therapy.
Further Information: PDF
DKFZ (German Cancer Research Center, Deutsches Krebsforschungszentrum)
Phone: +49-6221-42 2955
Contact
Dr. Ruth Herzog
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Pinpointing hydrogen isotopes in titanium hydride nanofilms
Although it is the smallest and lightest atom, hydrogen can have a big impact by infiltrating other materials and affecting their properties, such as superconductivity and metal-insulator-transitions. Now, researchers from…
A new way of entangling light and sound
For a wide variety of emerging quantum technologies, such as secure quantum communications and quantum computing, quantum entanglement is a prerequisite. Scientists at the Max-Planck-Institute for the Science of Light…
Telescope for NASA’s Roman Mission complete, delivered to Goddard
NASA’s Nancy Grace Roman Space Telescope is one giant step closer to unlocking the mysteries of the universe. The mission has now received its final major delivery: the Optical Telescope…